The UK Pathway for Cannabis-Based Products for Medicinal Use

An overview of how unlicensed cannabis-based medicines reach UK patients and what that means for overseas suppliers.

Context and Why It Matters

Since 2018, specialist doctors in the UK can prescribe cannabis-based products for medicinal use. Most products supplied are unlicensed medicines imported under specific controls.

Evidence and Current Practice

Import requires Home Office controlled-drug licensing alongside MHRA requirements for unlicensed medicines, with GMP expectations applying to the finished product.

Operational Considerations

Overseas cultivators typically supply through a UK-licensed importer or a GMP partner. Clear technical agreements define who holds each responsibility.

Bottom Line

Requirements evolve and should be confirmed with UK authorities and partners. Documentation discipline remains the common denominator.